July 29th, 2026 – Thera Health Policy & Access is pleased to announce the release of Episode 2 of TheraTalks, the interview series dedicated to engaging healthcare leaders, scientific experts, and policy innovators in meaningful discussions about the trends shaping the future of healthcare.

This latest episode features a conversation between José Luis Cárdenas Tomažič, Founder & Managing Director of Thera Health Policy & Access, and Dr. Guillermo Maligne, Senior Strategic Advisor – Medical & Scientific Affairs, who share their perspectives on how Artificial Intelligence (AI) is transforming the design, execution, and future of clinical research.

Throughout the discussion, José Luis and Guillermo explore how AI is already being applied across multiple stages of clinical development, from protocol design and patient recruitment to study monitoring, predictive analytics, and the interpretation of complex datasets. They also examine how these technologies may contribute to reducing operational inefficiencies, shortening development timelines, and improving the allocation of resources in clinical trials.

One of the central themes of the interview is the emergence of digital twins and predictive models, which leverage historical and real-world data to anticipate patient outcomes, support decision-making, and enhance clinical trial design. The conversation highlights both the opportunities these innovations present and the validation challenges that must be addressed before they can be widely adopted across healthcare systems and regulatory environments.

The episode also explores the growing role of digital biomarkers, an area in which AI is enabling the identification and interpretation of previously difficult-to-measure signals. Dr. Maligne discusses how these advances are opening new possibilities in therapeutic areas such as mental health, where traditional diagnostic tools often rely on subjective assessments. By incorporating digital biomarkers derived from behavioral patterns, microexpressions, and other measurable indicators, researchers may gain a more precise understanding of disease progression and treatment response.

Beyond technological innovation, the interview examines the broader challenges associated with AI adoption in clinical research, including regulatory expectations, evidence generation requirements, data quality, and the need for robust validation frameworks. While the technology’s potential is significant, both speakers emphasize that healthcare stakeholders must balance innovation with scientific rigor and patient safety.

As Senior Strategic Advisor – Medical & Scientific Affairs at Thera Health Policy & Access, Dr. Guillermo Maligne brings extensive experience in medical affairs, scientific strategy, and clinical development. His insights offer a valuable perspective on how emerging technologies are influencing the future of pharmaceutical innovation and evidence-based healthcare decision-making.

For Thera, TheraTalks continues to serve as a platform for sharing informed perspectives on the issues, innovations, and policy developments transforming healthcare globally. Through conversations with recognized experts, the series aims to foster dialogue that supports more effective, equitable, and sustainable health systems.

Episode 2 of TheraTalks is now available on Thera’s digital channels.

Watch the interview and join the conversation as we explore how Artificial Intelligence is shaping the future of clinical trials, medical innovation, and patient care.